Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Canglob D Forte is a veterinary biological product developed by Dyntec for the passive immunization of dogs against canine distemper. It consists of a purified hyperimmune globulin fraction (immunoglobulins) obtained from the blood of hyperimmunized dogs. Unlike active vaccines that stimulate the animal's own immune system to produce antibodies over time, Canglob D Forte provides immediate, pre-formed antibodies that specifically neutralize the Canine Distemper Virus (CDV). The "Forte" designation typically indicates a higher concentration or titer of specific antibodies compared to standard formulations. It is indicated for both the prevention of distemper in dogs following known or suspected exposure and as a therapeutic adjunct during the early stages of the disease to mitigate clinical symptoms and improve survival outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Canglob D Forte.